As February begins, major U.S. stock indexes have shown a strong start, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing record highs. In this context of market optimism, investors may find interest in exploring penny stocks—an investment area that often involves smaller or newer companies. Although the term "penny stocks" might seem outdated, these investments can still offer surprising value and potential for growth when backed by solid financial health.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
Dingdong (Cayman) (DDL)	$2.92	$580.77M	✅ 3 ⚠️ 1 View Analysis >
Waterdrop (WDH)	$1.87	$669.08M	✅ 4 ⚠️ 0 View Analysis >
WM Technology (MAPS)	$0.7107	$126.86M	✅ 4 ⚠️ 1 View Analysis >
LexinFintech Holdings (LX)	$2.96	$513.2M	✅ 4 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Cricut (CRCT)	$4.65	$974.03M	✅ 2 ⚠️ 2 View Analysis >
Nephros (NEPH)	$3.89	$42.72M	✅ 3 ⚠️ 2 View Analysis >
LifeVantage (LFVN)	$4.93	$64.86M	✅ 4 ⚠️ 4 View Analysis >
BAB (BABB)	$0.98	$7.15M	✅ 2 ⚠️ 3 View Analysis >
Lifetime Brands (LCUT)	$3.39	$75.22M	✅ 3 ⚠️ 2 View Analysis >

Let's dive into some prime choices out of the screener.

Cassava Sciences (SAVA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing drugs for neurodegenerative diseases, with a market cap of approximately $99.03 million.

Operations: Currently, the company does not report any revenue segments.

Market Cap: $99.03M

Cassava Sciences, a pre-revenue biotech company with a market cap of approximately US$99.03 million, faces significant challenges as it navigates the penny stock landscape. Despite having no debt and sufficient cash runway for over two years, the company remains unprofitable with increasing losses over five years. Recent clinical trials for Alzheimer's treatment did not meet key endpoints, leading to discontinued development in this area. Additionally, its proposed epilepsy trial is on hold pending further FDA information requests. The company's stock has been highly volatile recently and it has filed for a US$50 million equity offering to bolster finances amidst these setbacks.

SunCar Technology Group (SDA)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: SunCar Technology Group Inc. operates through its subsidiaries to offer cloud and mobile app-based auto eInsurance, technology, and auto services in the People’s Republic of China, with a market cap of approximately $195.26 million.

Operations: SunCar Technology Group generates revenue through three primary segments: Auto Service ($219.19 million), Technology Service ($47.40 million), and Auto eInsurance Service ($200.68 million).

Market Cap: $195.26M

SunCar Technology Group, with a market cap of US$195.26 million, operates in the auto services sector and has shown revenue growth, reporting US$338.08 million for the nine months ending September 2025. Despite this, it remains unprofitable with a net loss of US$7.49 million over the same period, although losses have decreased from the previous year. The company benefits from sufficient short-term assets to cover liabilities and has a cash runway exceeding three years if free cash flow continues to grow at historical rates. However, its board lacks experience and it faces high debt levels with a negative return on equity due to ongoing unprofitability.

Udemy (UDMY)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Udemy, Inc. is a learning company that operates a marketplace platform for skill acquisition across various global regions, with a market cap of approximately $683.23 million.

Operations: The company's revenue is derived from two main segments: Consumer, generating $265.77 million, and Enterprise, contributing $524.07 million.

Market Cap: $683.23M

Udemy, Inc., with a market cap of US$683.23 million, has recently become profitable and operates without debt, showcasing financial stability. The company reported annual sales of US$789.84 million and a net income of US$3.81 million for 2025, marking a turnaround from losses in prior years. Despite low return on equity at 1.8% and an inexperienced management team with an average tenure of 0.9 years, Udemy's strategic partnerships enhance its global reach and AI integration capabilities—exemplified by collaborations with OpenAI and Glean—positioning it as a dynamic player in the evolving educational technology landscape amidst its pending merger with Coursera valued at approximately $1 billion.

Taking Advantage

• Unlock our comprehensive list of 339 US Penny Stocks by clicking here.
• Curious About Other Options? Trump's oil boom is here — pipelines are primed to profit. Discover the 21 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.